Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis

Maldonado, Fabien; Moua, Teng; Rajagopalan, Srinivasan; Karwoski, Ronald A.; Raghunath, Sushravya; Decker, Paul; Hartman, Thomas E.; Bartholmai, Brian J.; Robb, Richard A.; Ryu, Jay H.

doi:10.1183/09031936.00071812

Cited by 205 publications

(149 citation statements)

References 29 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…Future studies should also consider whether sLOXL2, along with other promising prognostic IPF biomarkers (e.g. matrix metalloproteinase (MMP)1, MMP7, KL-6, periostin, surfactant protein-A and D, CC chemokine ligand 18, vascular endothelial growth factor and YKL-40) [19][20][21][22][23][24][25][26][27][28][29], as well as prognostic scores [30,31] and radiological modalities [32], might have prognostic value for helping physicians and patients anticipate the patient's IPF disease progression. This might include evaluation of serially collected sLOXL2 levels and their relationship to IPF acute exacerbations, which represent a terminal event for many IPF patients [33].…”

Section: Discussionmentioning

confidence: 99%

Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression

Chien¹,

et al. 2013

View full text Add to dashboard Cite

We evaluated whether lysyl oxidase-like 2 (LOXL2), which promotes cross-linking of collagen in pathological stroma, was detectable in serum from idiopathic pulmonary fibrosis (IPF) patients, and assessed its relationship with IPF disease progression.Patients from the ARTEMIS-IPF (n569) and the Genomic and Proteomic Analysis of Disease Progression in IPF (GAP) (n5104) studies were analysed. Baseline serum LOXL2 (sLOXL2) levels were compared with baseline clinical and physiological surrogates of disease severity, and the association with IPF disease progression was assessed using a classification and regression tree (CART) method. sLOXL2 correlated weakly with forced vital capacity and carbon monoxide diffusion capacity (r -0.24-0.05) in both cohorts. CART-determined thresholds were similar: ARTEMIS-IPF 800 pg?mL -1 and GAP 700 pg?mL -1. In ARTEMIS-IPF, higher sLOXL2 (.800 pg?mL -1 ) was associated with increased risk for disease progression (hazard ratio (HR) 5.41, 95% CI 1.65-17.73). Among GAP subjects with baseline spirometric data (n570), higher sLOXL2 levels (.700 pg?mL -1 ) were associated with more disease progression events (HR 1.78, 95% CI 1.01-3.11). Among all GAP subjects, higher sLOXL2 levels were associated with increased risk for mortality (HR 2.28, 95% CI 1.18-4.38).These results suggest that higher sLOXL2 levels are associated with increased risk for IPF disease progression. However, due to multiple limitations, these results require validation. Clinical trial: This study is registered at www.ClinicalTrials.gov with identifier number NCT00768300 and NCT 00373841.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression

Chien¹,

et al. 2013

View full text Add to dashboard Cite

show abstract

“…A machine-learning algorithm is then used to develop a predictive model for specific CT patterns [46]. MALDONADO et al [73] used a novel computer-aided system called CALIPER to quantify fibrosis in IPF based on unique HRCT texture patterns for ground-glass opacification, honeycombing and reticulation. The authors evaluated changes in those HRCT-derived patterns between two time points (3-15 months apart) and showed that changes in reticulation and total fibrosis were predictive of survival.…”

Section: Quantitative Computed Tomographymentioning

confidence: 99%

“…In addition, to date, it has primarily focused on evaluating the extent of parenchymal abnormalities as a surrogate for fibrosis severity, with less emphasis on other variables such as lung volumes [73,74] or the degree of traction bronchiectasis. The issue of CT protocol standardisation is nevertheless equally important, if not more so, for automated evaluation.…”

Section: Strengths and Limitations Of Ct In Staging Of Ipfmentioning

confidence: 99%

Evaluating disease severity in idiopathic pulmonary fibrosis

et al. 2017

View full text Add to dashboard Cite

Accurate assessment of idiopathic pulmonary fibrosis (IPF) disease severity is integral to the care provided to patients with IPF. However, to date, there are no generally accepted or validated staging systems. There is an abundance of data on using information acquired from physiological, radiological and pathological parameters, in isolation or in combination, to assess disease severity in IPF. Recently, there has been interest in using serum biomarkers and computed tomography-derived quantitative lung fibrosis measures to stage disease severity in IPF. This review will focus on the suggested methods for staging IPF, at baseline and on serial assessment, their strengths and limitations, as well as future developments.

show abstract

“…Several studies have identified independent predictors of mortality in patients with IPF, including age, respiratory hospitalisation, forced vital capacity (FVC) % predicted, and longitudinal change in FVC % pred [5][6][7][8][9][10][11][12][13][14][15][16]. The 6-min walk distance (6MWD), a practical and widely used measure of clinical status in patients with a variety of cardiopulmonary diseases [17][18][19][20][21][22], has recently been shown to be associated with the risk of mortality in patients with IPF [23][24][25]; however, the independent contribution of 6MWD to the risk of mortality has not been formally evaluated in a large, well-defined population of patients with IPF.…”

Section: Introductionmentioning

confidence: 99%

6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis

Bois

Albera

Bradford³

et al. 2013

Eur Respir J

197

163

View full text Add to dashboard Cite

6-min walk distance (6MWD) has recently been shown to be associated with the risk of mortality in patients with idiopathic pulmonary fibrosis (IPF); however, the independent contribution of 6MWD to the prediction of mortality risk has not been evaluated in a large, well-defined population of patients with IPF.A Cox proportional hazards model was used to characterise the relationship between risk factors of interest and all-cause mortality in IPF patients who completed a week 24 study visit in a clinical trial evaluating interferon c-1b (n5748). Risk factors of interest included the independent predictors of mortality in the previously published clinical prediction model together with 6MWD and 24-week change in 6MWD.Baseline 6MWD ,250 m was associated with a two-fold increase in the risk of mortality (hazard ratio 2.12, 95% CI 1.15-3.92) and a 24-week decline in 6MWD .50 m was associated with a nearly threefold increase in mortality risk (hazard ratio 2.73; 95% CI 1.60-4.66). Inclusion of 6MWD data improved model discrimination compared with the original model (C-statistic 0.80 (95% CI 0.76-0.85) versus 0.75 (0.71-0.79)).Both 6MWD and change in 6MWD are independent predictors of mortality in patients with IPF. The addition of 6MWD to the clinical prediction model improves model discrimination compared with the original model. @ERSpublications 6MWD indices independently predict mortality in IPF and improve performance of previous clinical prediction model

show abstract

Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis

Cited by 205 publications

References 29 publications

Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression

Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression

Evaluating disease severity in idiopathic pulmonary fibrosis

6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis

Contact Info

Product

Resources

About